Alkem funds ₹1,100 crore subsidiary deal to buy control of Occlutech
What's the deal? Alkem LaboratoriesDealroom has a profile for this one. Try Dealroom → has injected ₹1,100 crore into its wholly owned subsidiary Alkem MedtechDealroom has a profile for this one. Try Dealroom →, buying 79,36,50,794 equity shares at ₹13.86 each through a rights issue. The shares were allotted on July 15, 2026.
What's the endgame? The cash will let Alkem Medtech acquire a majority stake — at least 51% and up to 55% — in Occlutech Holding AG. The move deepens Alkem's push into medical devices, with a focus on cardiovascular and orthopedic fields.
Who is Alkem Medtech? Incorporated on March 27, 2024, it operates in the medical device sector and reported turnover of ₹15.13 crore for the year ended March 31, 2026 — up from nil in FY 2024-2025.
Why now? The deal, disclosed to the stock exchanges under Regulation 30 of the SEBI LODR Regulations, was paid in cash and conducted at arm's length. It does not constitute a related party transaction.
The signal: A pharma company is using a young, near-zero-revenue subsidiary as the vehicle to secure control of a device maker abroad — a bet on medical devices as the next growth lane beyond drugs.
Read more: scanx.trade
Image credit: Generated with Gemini
